Search Results 81-90 of 15557 for alt

1. A Study To Evaluate The Safety And Effectiveness Of Pembrolizumab Compared To Placebo In Resected High-risk Stage II Melanoma Patients - Mayo Clinic

   Hematological · Renal · Hepatic · Coagulation · ALT (SGPT) = alanine aminotransferase (serum glutamic pyruvic transaminase); AST (SGOT) = aspartate aminotransferase ...

2. A Study to Evaluate Hepatotoxicity Risk Associated with TURALIO™ (pexidartinib) Treatment - Mayo Clinic

   AST or ALT > 3 × ULN with concurrent total bilirubin > 2 × ULN;; Isolated total bilirubin > 2 × ULN (excluding patients with Gilbert's syndrome);; Isolated ...

3. A Study To Evaluate The Safety And Effectiveness Of Obeticholic Acid Treatment On People With Non-Alcoholic Steatohepatitis With Fibrosis - Mayo Clinic

   ALT >1.5× upper limit of normal (ULN). For subjects with a historical biopsy, is either not taking or is on stable doses of TZDs/glitazones or vitamin E for ...

4. Myositis Interstitial Lung Disease Nintedanib Trial - Mayo Clinic

   baseline. 19. Safety laboratory abnormality as any one of below 1. Aspartate transferase (AST), alanine aminotransferase (ALT) > 1.5 x ULN at screening ...

5. Dual-Hormone Control of Post-absorptive and Post-prandial Glucose in Type 1 Diabetes - Mayo Clinic

   Abnormal liver function test results (ALT >2 times the upper limit of normal). Abnormal renal function test results (creatinine >1.4 in women and >1.5 in ...

6. A Phase II, Multicenter Study Of The EZH2 Inhibitor Tazemetostat In Adult Subjects With INI1-Negative Tumors Or Relapsed/Refractory Synovial Sarcoma - Mayo Clinic

   If attributed to tumor involvement, AST and ALT <5×ULN. Subjects a history of hepatitis (Exclusion Criterion No. 11) must have ALT within the normal range.

7. Comparison Of Anti-coagulation And Anti-Platelet Therapies For Intracranial Vascular Atherostenosis - Mayo Clinic

   or ALT > 3 x normal, cirrhosis), or CrCl < 15 mL/min or on dialysis - Major surgery (including open femoral, aortic, or carotid surgery, cardiac) within

8. FXR Effect On Severe Alcohol-Associated Hepatitis (FRESH) Study - Mayo Clinic

   AST/ALT ratio ≥ 1.5;; Maddrey's Discriminant Factor (MDF) ≥ 32 and ≤ 60;; MELD-Na score 18 to 25 (inclusive). Onset of jaundice within 8 weeks from the ...

9. Publications - Mithri Junna, M.D. - Mayo Clinic

   Chang JL, Goldberg AN, Alt JA, Mohammed A, Ashbrook L, Auckley D, Ayappa I, Bakhtiar H, Barrera JE, Bartley BL, Billings ME, Boon MS, Bosschieter P ...

10. Pazopanib Hydrochloride in Treating Patients with Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma - Mayo Clinic

    ... (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≤ 2.5 x ULN; NOTE: Subjects who have both bilirubin > ULN and AST/ALT > ULN are not eligible; Alkaline ...